| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
The aim of this study was to evaluate the risk factors and prevalence of adverse events among epilepsy patients. We retrospectively reviewed 25,419 epilepsy patients. The incidence of severe hyponatremia, thrombocytopenia, pancytopenia, liver injury was 1.6% (N=453), 2.0 % (N=516), 0.67 % (N=171), and 1.2 % (N=316), respectively. When severe hyponatremia was defined as a serum sodium level < 130 mEq/L, old age, low body weight, and concomitant use of phenobarbital, benzodiazepines, or antipsychotics were risk factors for hyponatremia. Also, the sodium level decreased as the carbamazepine dose increased. In patients receiving carbamazepine and valproate, there was 17-fold higher prevalence of hyponatremia. When a platelet count less than 100,000/ mm was defined as thrombocytopenia, the risk factors were a antiepileptic polypharmacy, concomitant use of valproate and rufinamide. Our findings can help clinicians to avoid adverse events in patients with epilepsy.
|
